JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1040/0.01/16.08.24 Share Price

Warrant

DE000JB7W586

Real-time Bid/Ask 13:18:44 05/07/2024 BST
0.3 EUR / 0.33 EUR +5.00% Intraday chart for JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1040/0.01/16.08.24
Current month-28.57%
1 month+42.86%
Date Price Change
05/07/24 0.3 0.00%
04/07/24 0.3 -28.57%
03/07/24 0.42 +23.53%
02/07/24 0.34 -22.73%
01/07/24 0.44 +4.76%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 12:01 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
Issuer J.P. Morgan
WKN JB7W58
ISINDE000JB7W586
Date issued 18/12/2023
Strike 1,040 $
Maturity 16/08/2024 (42 Days)
Parity 100 : 1
Emission price 0.3
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.58
Lowest since issue 0.12
Delta0.48x
Omega 14.82
Premium4.78x
Gearing31.03x
Moneyness 0.9847
Difference Strike 15.91 $
Difference Strike %+1.53%
Spread 0.03
Spread %9.38%
Theoretical value 0.3150
Implied Volatility 27.80 %
Total Loss Probability 55.80 %
Intrinsic value 0.000000
Present value 0.3150
Break even 1,074.09 €
Theta-0.04x
Vega0.01x
Rho0x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,024 USD
Average target price
1,051 USD
Spread / Average Target
+2.67%
Consensus